Anti-TGF-b1 antibody therapy in patients with diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 28, Issue 3, 2017, Pages 953-962

  Voelker, James ^a   Berg, Paul H ^a   Sheetz, Matthew ^a   Duffin, Kevin ^a   Shen, Tong ^a   Moser, Brian ^a   Greene, Tom ^b   Blumenthal, Samuel S ^c   Rychlik, Ivan ^d   Yagil, Yoram ^e   Zaoui, Philippe ^f   Lewis, Julia B ^g  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d CHARLES UNIVERSITY   (Czech Republic)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; CREATININE; CYSTATIN C; FIBRONECTIN; KIDNEY INJURY MOLECULE 1; MATRILYSIN; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1 ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AUTOIMMUNITY; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART ARREST; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOGLYCEMIA; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; SUDDEN DEATH; TREATMENT OUTCOME; VOLUME OF DISTRIBUTION; CLINICAL TRIAL; DIABETIC NEPHROPATHIES; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85021850104     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015111230     Document Type: Conference Paper

References (38)

1. Anand S, Bitton A, Gaziano T: The gap between estimated incidence of end-stage renal disease and use of therapy. PLoS One 8: E72860, 2013.
2. United States Renal Data System: 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2014.
3. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J: Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305: 2532-2539, 2011.
4. International Diabetes Federation: IDF Diabetes Atlas, 6th Ed., Brussels, Belgium, International Diabetes Federation, 2013.
5. Hu FB: Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care 34: 1249-1257, 2011.
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med 345: 851-860, 2001.
7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med 345: 861- 869, 2001.
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: 1-150, 2013.
9. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L: Changes in diabetes-related complications in the United States, 1990-2010. N Engl JMed 370: 1514-1523, 2014.
10. Böttinger EP: TGF-b in renal injury and disease. Semin Nephrol 27: 309-320, 2007.
11. Miyazono K, Kusanagi K, Inoue H: Divergence and convergence of TGF-b/BMP signaling. J Cell Physiol 187: 265-276, 2001.
12. Massagué J: TGFbeta in Cancer. Cell 134: 215-230, 2008.
13. Massagué J: TGF-b signal transduction. Annu Rev Biochem 67: 753- 791, 1998.
14. Attisano L, Wrana JL: Signal transduction by the TGF-b superfamily. Science 296: 1646-1647, 2002.
15. Pohlers D, Brenmoehl J, Löffler I, Müller CK, Leipner C, Schultze- Mosgau S, Stallmach A, Kinne RW, Wolf G: TGF-b and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta 1792: 746-756, 2009.
16. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-Term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-b antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97: 8015-8020, 2000.
17. Chen S, Iglesias-de la Cruz MC, Jim B, Hong SW, Isono M, Ziyadeh FN: Reversibility of established diabetic glomerulopathy by anti-TGF-b antibodies in db/db mice. Biochem Biophys Res Commun 300: 16-22, 2003.
18. Yu L, Border WA, Huang Y, Noble NA: TGF-b isoforms in renal fibrogenesis. Kidney Int 64: 844-856, 2003.
19. Rowlinson S, Brault P, Galbreath E, Jones B, Mcentire J, McKinney T, Shanafelt A, Syed S, Voelker J, Zhang T, Dunn S, Heuer J, Sharma K: An anti-TGF-b1 specific mAb demonstrates renal efficacy equivalent to a pan neutralizing mAb in the rat anti-Thy1.1 and mouse db/db models [Abstract]. J Am Soc Nephrol 18: 414A, SA-PO329, 2007.
20. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor b 1. Nature 346: 371-374, 1990.
21. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 86: 453-462, 1990.
22. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
23. Ziyadeh FN:Mediators of diabetic renal disease: The case for tgf-Beta as the major mediator. J Am Soc Nephrol 15[Suppl 1]: S55-S57, 2004.
24. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA: Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 49: 461-469, 1996.
25. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB, Weisberg LS: Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46: 854- 859, 1997.
26. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlateswith long-Term renoprotection in insulin-dependent diabetic patients.Am J Kidney Dis 34: 818-823, 1999.
27. Esmatjes E, Flores L, Iñigo P, Lario S, Ruilope LM, Campistol JM: Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 16[Suppl 1]: 90-93, 2001.
28. Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 39: 486-492, 2002.
29. Benigni A, Zoja C, Campana M, Corna D, Sangalli F, Rottoli D, Gagliardini E, Conti S, Ledbetter S, Remuzzi G: Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron, Exp Nephrol 104: E158-e168, 2006.
30. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F: A phase 1, single-dose study of fresolimumab, an anti-TGF-b antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79: 1236-1243, 2011.
31. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB: Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22: 1144-1151, 2011.
32. Ma LJ, Jha S, Ling H, Pozzi A, Ledbetter S, Fogo AB: Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 65: 106-115, 2004.
33. Khanna AK, Plummer MS, Hilton G, Pieper GM, Ledbetter S: Antitransforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: potential of therapeutic applications. Circulation 110: 3822-3829, 2004.
34. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA: Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 66: 1774-1784, 2004.
35. Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J:GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64: 821-835, 2014.
36. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR: Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 14[Suppl 2]: S154-S165, 2003.
37. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 33[Suppl 1]: S62-S69, 2010.
38. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254, 2006.